Innovations in Evaluating Statin Benefit and Efficacy in Staphylococcus aureus Intracellular Infection Management
Abstract
:1. Introduction
2. Supporting Evidence from In Vitro and In Vivo Studies
3. Contradictory Evidence from Randomized Clinical Trial Data
4. Settings Where Biology Suggests Statins May Offer Protection against Infection
4.1. Cardiac Device Infection
4.2. Hip and Knee Replacement Infection
5. Innovations to Evaluate Statin Efficacy
6. Summary Statement
Funding
Institutional Review Board Statement
Conflicts of Interest
References
- Zumla, A.; Rao, M.; Wallis, R.S.; Kaufmann, S.H.; Rustomjee, R.; Mwaba, P.; Vilaplana, C.; Yeboah-Manu, D.; Chakaya, J.; Ippolito, G.; et al. Host-directed therapies for infectious diseases: Current status, recent progress, and future prospects. Lancet Infect. Dis. 2016, 16, e47–e63. [Google Scholar] [CrossRef] [Green Version]
- Hennessy, E.; Adams, C.; Reen, F.J.; O’Gara, F. Is There Potential for Repurposing Statins as Novel Antimicrobials? Antimicrob. Agents Chemother. 2016, 60, 5111–5121. [Google Scholar] [CrossRef] [Green Version]
- Caffrey, A.R.; Timbrook, T.T.; Noh, E.; Sakoulas, G.; Opal, S.M.; Nizet, V.; LaPlante, K.L. Evidence To Support Continuation of Statin Therapy in Patients with Staphylococcus aureus Bacteremia. Antimicrob. Agents Chemother. 2017, 61, E02228-16. [Google Scholar] [CrossRef] [Green Version]
- Parihar, S.P.; Guler, R.; Brombacher, F. Statins: A viable candidate for host-directed therapy against infectious diseases. Nat. Rev. Immunol. 2019, 19, 104–117. [Google Scholar] [CrossRef]
- Kaufmann, S.H.E.; Dorhoi, A.; Hotchkiss, R.S.; Bartenschlager, R. Host-directed therapies for bacterial and viral infections. Nat. Rev. Drug Discov. 2018, 17, 35–56. [Google Scholar] [CrossRef]
- Wright, J.A.; Nair, S.P. Interaction of staphylococci with bone. Int. J. Med. Microbiol. 2010, 300, 193–204. [Google Scholar] [CrossRef] [Green Version]
- Arbibe, L.; Mira, J.P.; Teusch, N.; Kline, L.; Guha, M.; Mackman, N.; Godowski, P.J.; Ulevitch, R.J.; Knaus, U.G. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat. Immunol. 2000, 1, 533–540. [Google Scholar] [CrossRef]
- Johnson, D.I. Cdc42: An essential Rho-type GTPase controlling eukaryotic cell polarity. Microbiol. Mol. Biol. Rev. 1999, 63, 54–105. [Google Scholar] [CrossRef] [Green Version]
- Zheng, Y.; Bagrodia, S.; Cerione, R.A. Activation of phosphoinositide 3-kinase activity by Cdc42Hs binding to p85. J. Biol. Chem. 1994, 269, 18727–18730. [Google Scholar] [CrossRef]
- Fraley, T.S.; Tran, T.C.; Corgan, A.M.; Nash, C.A.; Hao, J.; Critchley, D.R.; Greenwood, J.A. Phosphoinositide binding inhibits alpha-actinin bundling activity. J. Biol. Chem. 2003, 278, 24039–24045. [Google Scholar] [CrossRef]
- Horn, M.P.; Knecht, S.M.; Rushing, F.L.; Birdsong, J.; Siddall, C.P.; Johnson, C.M.; Abraham, T.N.; Brown, A.; Volk, C.B.; Gammon, K.; et al. Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J. Pharmacol. Exp. Ther. 2008, 326, 135–143. [Google Scholar] [CrossRef] [Green Version]
- Proctor, R.A.; von Eiff, C.; Kahl, B.C.; Becker, K.; McNamara, P.; Herrmann, M.; Peters, G. Small colony variants: A pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 2006, 4, 295–305. [Google Scholar] [CrossRef]
- Tuchscherr, L.; Medina, E.; Hussain, M.; Volker, W.; Heitmann, V.; Niemann, S.; Holzinger, D.; Roth, J.; Proctor, R.A.; Becker, K.; et al. Staphylococcus aureus phenotype switching: An effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol. Med. 2011, 3, 129–141. [Google Scholar] [CrossRef]
- Jubrail, J.; Morris, P.; Bewley, M.A.; Stoneham, S.; Johnston, S.A.; Foster, S.J.; Peden, A.A.; Read, R.C.; Marriott, H.M.; Dockrell, D.H. Inability to sustain intraphagolysosomal killing of Staphylococcus aureus predisposes to bacterial persistence in macrophages. Cell Microbiol. 2016, 18, 80–96. [Google Scholar] [CrossRef] [Green Version]
- Thwaites, G.E.; Gant, V. Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus? Nat. Rev. Microbiol. 2011, 9, 215–222. [Google Scholar] [CrossRef]
- Endo, A. The discovery and development of HMG-CoA reductase inhibitors. 1992. Atheroscler. Suppl. 2004, 5, 67–80. [Google Scholar] [CrossRef]
- Caffo, L.; Sneed, B.L.; Burcham, C.; Reed, K.; Hahn, N.C.; Bell, S.; Downham, O.; Evans, M.D.; Fullenkamp, C.R.; Drinnon, T.K.; et al. Simvastatin and ML141 decrease intracellular Streptococcus pyogenes infection. Curr. Pharm. Biotechnol. 2019, 20, 733–744. [Google Scholar] [CrossRef]
- Stankiewicz, T.E.; Haaning, K.L.; Owens, J.M.; Jordan, A.S.; Gammon, K.; Bruns, H.A.; McDowell, S.A. GTPase activating protein function of p85 facilitates uptake and recycling of the beta1 integrin. Biochem. Biophys. Res. Commun. 2010, 391, 443–448. [Google Scholar] [CrossRef] [Green Version]
- McDowell, S.A.; Ma, Y.; Kusano, R.; Akinbi, H.T. Simvastatin is protective during Staphylococcus aureus pneumonia. Curr. Pharm. Biotechnol. 2011, 12, 1455–1462. [Google Scholar] [CrossRef] [Green Version]
- Benati, D.; Ferro, M.; Savino, M.T.; Ulivieri, C.; Schiavo, E.; Nuccitelli, A.; Pasini, F.L.; Baldari, C.T. Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus. J. Leukoc. Biol. 2010, 87, 433–442. [Google Scholar] [CrossRef]
- Chow, O.A.; von Kockritz-Blickwede, M.; Bright, A.T.; Hensler, M.E.; Zinkernagel, A.S.; Cogen, A.L.; Gallo, R.L.; Monestier, M.; Wang, Y.; Glass, C.K.; et al. Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 2010, 8, 445–454. [Google Scholar] [CrossRef] [Green Version]
- Merx, M.W.; Liehn, E.A.; Janssens, U.; Lutticken, R.; Schrader, J.; Hanrath, P.; Weber, C. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004, 109, 2560–2565. [Google Scholar] [CrossRef] [Green Version]
- Merx, M.W.; Liehn, E.A.; Graf, J.; van de Sandt, A.; Schaltenbrand, M.; Schrader, J.; Hanrath, P.; Weber, C. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005, 112, 117–124. [Google Scholar] [CrossRef] [Green Version]
- Nagendran, M.; McAuley, D.F.; Kruger, P.S.; Papazian, L.; Truwit, J.D.; Laffey, J.G.; Thompson, B.T.; Clarke, M.; Gordon, A.C. Statin therapy for acute respiratory distress syndrome: An individual patient data meta-analysis of randomised clinical trials. Intensive Care Med. 2017, 43, 663–671. [Google Scholar] [CrossRef]
- Kruger, P.S.; Terblanche, M. Statins in patients with sepsis and ARDS: Is it over? No. Intensive Care Med. 2017, 43, 675–676. [Google Scholar] [CrossRef] [Green Version]
- Alhazzani, W.; Truwit, J. Statins in patients with sepsis and ARDS: Is it over? Yes. Intensive Care Med. 2017, 43, 672–674. [Google Scholar] [CrossRef] [Green Version]
- Kruger, P.; Bailey, M.; Bellomo, R.; Cooper, D.J.; Harward, M.; Higgins, A.; Howe, B.; Jones, D.; Joyce, C.; Kostner, K.; et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am. J. Respir. Crit Care Med. 2013, 187, 743–750. [Google Scholar] [CrossRef]
- van Rein, N.; Cannegieter, S.C.; le Cessie, S.; Rosendaal, F.R.; Reitsma, P.H.; van der Meer, F.J.; Lijfering, W.M. Statins and Risk of Bleeding: An Analysis to Evaluate Possible Bias Due to Prevalent Users and Healthy User Aspects. Am. J. Epidemiol. 2016, 183, 930–936. [Google Scholar] [CrossRef] [Green Version]
- Emilsson, L.; Garcia-Albeniz, X.; Logan, R.W.; Caniglia, E.C.; Kalager, M.; Hernan, M.A. Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer. JAMA Oncol. 2018, 4, 63–70. [Google Scholar] [CrossRef]
- Suissa, S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol. Drug Saf. 2007, 16, 241–249. [Google Scholar] [CrossRef]
- Dormuth, C.R.; Patrick, A.R.; Shrank, W.H.; Wright, J.M.; Glynn, R.J.; Sutherland, J.; Brookhart, M.A. Statin adherence and risk of accidents: A cautionary tale. Circulation 2009, 119, 2051–2057. [Google Scholar] [CrossRef] [PubMed]
- Greenspon, A.J.; Patel, J.D.; Lau, E.; Ochoa, J.A.; Frisch, D.R.; Ho, R.T.; Pavri, B.B.; Kurtz, S.M. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J. Am. Coll. Cardiol. 2011, 58, 1001–1006. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lambert, C.T.; Tarakji, K.G. Cardiac implantable electronic device infection. Cleve Clin. J. Med. 2017, 84, 47–53. [Google Scholar] [CrossRef]
- Rizwan Sohail, M.; Henrikson, C.A.; Jo Braid-Forbes, M.; Forbes, K.F.; Lerner, D.J. Increased long-term mortality in patients with cardiovascular implantable electronic device infections. Pacing Clin. Electrophysiol. 2015, 38, 231–239. [Google Scholar] [CrossRef]
- Garzoni, C.; Kelley, W.L. Staphylococcus aureus: New evidence for intracellular persistence. Trends Microbiol. 2009, 17, 59–65. [Google Scholar] [CrossRef] [PubMed]
- Que, Y.A.; Haefliger, J.A.; Piroth, L.; Francois, P.; Widmer, E.; Entenza, J.M.; Sinha, B.; Herrmann, M.; Francioli, P.; Vaudaux, P.; et al. Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J. Exp. Med. 2005, 201, 1627–1635. [Google Scholar] [CrossRef] [PubMed]
- McAuley, D.; Charles, P.E.; Papazian, L. Statins in patients with sepsis and ARDS: Is it over? We are not sure. Intensive Care Med. 2017, 43, 677–679. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alzahrani, T.; Liappis, A.P.; Baddour, L.M.; Karasik, P.E. Statin use and the risk of cardiovascular implantable electronic device infection: A cohort study in a veteran population. Pacing Clin. Electrophysiol. 2018, 41, 284–289. [Google Scholar] [CrossRef]
- OECD. Health at a Glance 2015: OECD Indicators; OECD Publishing: Paris, France, 2015. [Google Scholar] [CrossRef]
- Wolford, M.L.; Palso, K.; Bercovitz, A. Hospitalization for Total Hip Replacement among Inpatients Aged 45 and Over: United States, 2000–2010; NCHS Data Brief no 186; National Center for Health Statistics: Hyattsville, MD, USA, 2015; pp. 1–8.
- Williams, S.N.; Wolford, M.L.; Bercovitz, A. Hospitalization for Total Knee Replacement among Inpatients Aged 45 and Over: United States, 2000–2010; NCHS Data Brief no 210; National Center for Health Statistics: Hyattsville, MD, USA, 2015; pp. 1–8.
- Kurtz, S.; Ong, K.; Lau, E.; Mowat, F.; Halpern, M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J. Bone Jt. Surg. Am. 2007, 89, 780–785. [Google Scholar] [CrossRef]
- Kurtz, S.M.; Lau, E.; Watson, H.; Schmier, J.K.; Parvizi, J. Economic burden of periprosthetic joint infection in the United States. J. Arthroplast. 2012, 27, 61–65.e61. [Google Scholar] [CrossRef]
- Tande, A.J.; Patel, R. Prosthetic joint infection. Clin. Microbiol. Rev. 2014, 27, 302–345. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kurtz, S.M.; Lau, E.C.; Son, M.S.; Chang, E.T.; Zimmerli, W.; Parvizi, J. Are We Winning or Losing the Battle with Periprosthetic Joint Infection: Trends in Periprosthetic Joint Infection and Mortality Risk for the Medicare Population. J. Arthroplast. 2018, 33, 3238–3245. [Google Scholar] [CrossRef] [PubMed]
- Kunutsor, S.K.; Whitehouse, M.R.; Webb, J.; Toms, A.; Stockley, I.; Taylor, A.; Jones, S.; Wilson, M.; Burston, B.; Board, T.; et al. Re-infection outcomes following one- and two-stage surgical revision of infected hip prosthesis in unselected patients: Protocol for a systematic review and an individual participant data meta-analysis. Syst. Rev. 2015, 4, 58. [Google Scholar] [CrossRef] [Green Version]
- Kunutsor, S.K.; Whitehouse, M.R.; Lenguerrand, E.; Blom, A.W.; Beswick, A.D.; Team, I. Re-Infection Outcomes Following One- And Two-Stage Surgical Revision of Infected Knee Prosthesis: A Systematic Review and Meta-Analysis. PLoS ONE 2016, 11, e0151537. [Google Scholar] [CrossRef] [Green Version]
- Prokopetz, J.J.; Losina, E.; Bliss, R.L.; Wright, J.; Baron, J.A.; Katz, J.N. Risk factors for revision of primary total hip arthroplasty: A systematic review. BMC Musculoskelet. Disord. 2012, 13, 251. [Google Scholar] [CrossRef] [Green Version]
- Guo, G.; Wang, J.; You, Y.; Tan, J.; Shen, H. Distribution characteristics of Staphylococcus spp. in different phases of periprosthetic joint infection: A review. Exp. Ther. Med. 2017, 13, 2599–2608. [Google Scholar] [CrossRef] [Green Version]
- Lower, S.K.; Lamlertthon, S.; Casillas-Ituarte, N.N.; Lins, R.D.; Yongsunthon, R.; Taylor, E.S.; DiBartola, A.C.; Edmonson, C.; McIntyre, L.M.; Reller, L.B.; et al. Polymorphisms in fibronectin binding protein A of Staphylococcus aureus are associated with infection of cardiovascular devices. Proc. Natl. Acad. Sci. USA 2011, 108, 18372–18377. [Google Scholar] [CrossRef] [Green Version]
- Hos, N.J.; Rieg, S.; Kern, W.V.; Jonas, D.; Fowler, V.G.; Higgins, P.G.; Seifert, H.; Kaasch, A.J. Amino acid alterations in fibronectin binding protein A (FnBPA) and bacterial genotype are associated with cardiac device related infection in Staphylococcus aureus bacteraemia. J. Infect. 2015, 70, 153–159. [Google Scholar] [CrossRef]
- Eichenberger, E.M.; Thaden, J.T.; Sharma-Kuinkel, B.; Park, L.P.; Rude, T.H.; Ruffin, F.; Hos, N.J.; Seifert, H.; Rieg, S.; Kern, W.V.; et al. Polymorphisms in Fibronectin Binding Proteins A and B among Staphylococcus aureus Bloodstream Isolates Are Not Associated with Arthroplasty Infection. PLoS ONE 2015, 10, e0141436. [Google Scholar] [CrossRef]
- Lalmohamed, A.; van Staa, T.P.; Vestergaard, P.; Leufkens, H.G.M.; de Boer, A.; Emans, P.; Cooper, C.; de Vries, F. Statins and Risk of Lower Limb Revision Surgery: The Influence of Differences in Study Design Using Electronic Health Records From the United Kingdom and Denmark. Am. J. Epidemiol. 2016, 184, 58–66. [Google Scholar] [CrossRef] [Green Version]
- Cook, M.J.; Sorial, A.K.; Lunt, M.; Board, T.N.; O’Neill, T.W. Effect of timing and duration of statin exposure on risk of hip or knee revision arthroplasty: A population-based cohort study. J. Rheumatol. 2020, 47, 441–448. [Google Scholar] [CrossRef] [PubMed]
- Setoguchi, S.; Glynn, R.J.; Avorn, J.; Mogun, H.; Schneeweiss, S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007, 115, 27–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Farwell, W.R.; Scranton, R.E.; Lawler, E.V.; Lew, R.A.; Brophy, M.T.; Fiore, L.D.; Gaziano, J.M. The association between statins and cancer incidence in a veterans population. J. Natl. Cancer Inst. 2008, 100, 134–139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bromilow, J.; Schuster Bruce, M.J. The use of statins in intensive care unit patients with sepsis. Anaesth. Intensive Care 2007, 35, 256–258. [Google Scholar] [CrossRef] [Green Version]
- Mahboobi, S.K.; Shohat, E.Z.; Jellinek, S.P.; Rose, M. Systemic infections can decrease the threshold of statin-induced muscle injury. South Med. J. 2006, 99, 403–405. [Google Scholar]
- Vincent, A.; Miller, J.A. Statins for sepsis: A cautionary note. Intensive Care Med. 2006, 32, 795. [Google Scholar]
- Newman, C.B.; Preiss, D.; Tobert, J.A.; Jacobson, T.A.; Page, R.L.; Goldstein, L.B.; Chin, C.; Tannock, L.R.; Miller, M.; Raghuveer, G.; et al. Statin safety and associated adverse events: A scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 2019, 39, e38–e81, Erratum in: Arterioscler. Thromb. Vasc. Biol. 2019, 39, e158. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nesson, E.T.; McDowell, S.A. Innovations in Evaluating Statin Benefit and Efficacy in Staphylococcus aureus Intracellular Infection Management. Int. J. Mol. Sci. 2022, 23, 13006. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232113006
Nesson ET, McDowell SA. Innovations in Evaluating Statin Benefit and Efficacy in Staphylococcus aureus Intracellular Infection Management. International Journal of Molecular Sciences. 2022; 23(21):13006. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232113006
Chicago/Turabian StyleNesson, Erik T., and Susan A. McDowell. 2022. "Innovations in Evaluating Statin Benefit and Efficacy in Staphylococcus aureus Intracellular Infection Management" International Journal of Molecular Sciences 23, no. 21: 13006. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232113006